Medical issues in cancer survivors - A review

Cancer Journal

Volumn 14, Issue 6, 2008, Pages 375-387

  Miller, Kenneth D ^a   Triano, Laura R ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Cancer survivor; Late effects of cancer treatment; Long term complications of cancer treatment; Survivorship

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; GLUCOCORTICOID; IFOSFAMIDE; LAPATINIB; LETROZOLE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NITROSOUREA; PAMIDRONIC ACID; PREDNISONE; PROCARBAZINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT RESPIRATORY DISTRESS SYNDROME; AMNESIA; ARM SWELLING; ARTHRALGIA; ARTHRITIS; ATHEROSCLEROSIS; AVASCULAR NECROSIS; BLOOD VESSEL INJURY; BONE NECROSIS; BRAIN DISEASE; BRAIN LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CATARACT; CEREBELLUM DISEASE; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; CHRONIC PAIN; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; COORDINATION DISORDER; CRANIAL NEUROPATHY; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DIASTOLIC DYSFUNCTION; DIGESTIVE SYSTEM CANCER; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; ENTERITIS; ENTEROPATHY; ESOPHAGUS CANCER; EXTRAPYRAMIDAL SYNDROME; FECES INCONTINENCE; FIBROMYALGIA; FRACTURE; GAIT DISORDER; GASTRITIS; GASTROINTESTINAL MOTILITY DISORDER; GERM CELL TUMOR; GLAUCOMA; GLUCOSE TOLERANCE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEALTH CARE; HEARING; HEARING LOSS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VALVE REGURGITATION; HEART VALVE STENOSIS; HEART VENTRICLE FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; HYDRONEPHROSIS; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; ILEUS; INNER EAR DISEASE; INTESTINE FISTULA; INTESTINE OBSTRUCTION; INTRAOCULAR PRESSURE; IRON OVERLOAD; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; KIDNEY CANCER; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LARYNX CANCER; LEUKOENCEPHALOPATHY; LIFE; LIVER FIBROSIS; LUNG CANCER; LUNG CARCINOMA; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG INFECTION; LUNG METASTASIS; LYMPHEDEMA; METASTASIS; MITRAL VALVE DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NECROSIS; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTOXICITY; OPTIC NERVE ATROPHY; OPTIC NERVE LESION; OSTEOARTHRITIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PANCREAS INSUFFICIENCY; PERCEPTION DEAFNESS; PERICARDITIS; PERIPHERAL NEUROPATHY; PHYSICIAN; PNEUMONIA; POLYARTHRITIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RAYNAUD PHENOMENON; RECTUM CANCER; RECURRENT INFECTION; RETINA INJURY; RETINOPATHY; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SPINAL CORD DISEASE; STOMACH CANCER; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTOLIC DYSFUNCTION; TESTIS CANCER; THERAPY EFFECT; THYROID DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; UROGENITAL TRACT CANCER; VASCULAR DISEASE; VASCULITIS; VOMITING;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; HUMANS; NEOPLASMS; NEUROMUSCULAR DISEASES; RADIOTHERAPY; SURGICAL PROCEDURES, OPERATIVE; SURVIVORS;

EID: 58149266719     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31818ee3dc     Document Type: Review

References (84)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
2. Rao AV, Demark-Wahnefried W. The older cancer survivor. Crit Rev Oncol Hematol. 2006;60:131-143.
3. Schultz PN, Beck ML, Stava C, et al. Health profiles of 5836 long-term cancer survivors. Int J Cancer. 2003;104:488-495.
4. Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy. Paediatr Drugs. 2005;7:187-202.
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
6. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
7. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med. 1979;91:710-717.
8. Minow RA, Benjamin RS, Lee ET, et al. Adriamycin cardiomyopathy: risk factors. Cancer. 1977;39:1397-1402.
9. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
10. Cook-Burns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61:58-66.
11. Suter TM, Cook-Burns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:73-183.
12. Yeh ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.
13. Yeh ETH. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006;57:485-498.
14. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
15. Gottdiener JS, Katin MJ, Borer JS, et al. Late cardiac effects of therapeutic mediastinal irradiation. N EnglJ Med. 1983;308:569-572.
16. Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003;13:346-356.
17. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55-75.
18. Carlson RG, Mayfield WR, Normann S, et al. Radiation-associated valvular disease. Chest. 1991;99:538-545.
19. Applefeld MM, Cole JF, Pollock SH, et al. The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease. Ann Intern Med. 1981;94:338-341.
20. Hooning MJ, Botma A, Aleman BMP, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365-375.
21. Prosnitz RG, Marks LB. Radiation-induced heart disease: vigilance is still required. J Clin Oncol. 2005;23:7391-7394.
22. Dunsmore LD, LoPonte MA, Dunsmore RA. Radiation-induced coronary artery disease. J Am Coll Cardiol. 1986;8:239-244.
23. Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term nsk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107:2912-2919.
24. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11:1208-1215.
25. Gaya AM, Ashford RFU. Cardiac complications of radiation therapy. Clin Oncol. 2005;17:153-159.
26. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-2837.
27. Gayed IW, Liu HH, Yusuf SW, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Sucl Med. 2006;47:1756-1762.
28. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal radiation. J Am Coll Cardiol. 2003;42: 743-749.
29. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol. 2003;92:226-230.
30. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617-624.
31. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumors. Ann Oncol. 2003;14:91-96.
32. Uzel I, Ozguroglu M, Uzel B, et al. Delayed onset bleomycin-induced pneumonitis. Urology. 2005;66:195.
33. Granena A, Carreras E, Rozman C, et al. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Bone Marrow Transplant. 1993;453-458.
34. Carver JR, Shaprio CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25: 3991-4008.
35. Yahalom J, Portlock CS. Long-term cardiac and pulmonary complications of cancer therapy. Hematol Oncol Clin North Am. 2008;22:305-318.
36. Dahlberg M, Glimelius B, Graf W, et al. Preoperative irradiation affects functional results after surgery for rectal cancer. Dis Colon Rectum. 1998;41:543-551.
37. Sher ME, Bauer J. Radiation-induced enteropathy. Lancet. 1990:85: 121-128.
38. Andreyev HJN. Gastrointestinal problems after pelvic radiotherapy: the past, the present, and the future. Clin Oncol. 2007;19:790-799.
39. Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterol. 2005: 128:819-824.
40. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: hepatocellular injury. Clin Liver Dis. 2007;11:641-662.
41. Iqbal N, Salzman D, Lazenby A, et al. Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol. 2000;95:3034-3038.
42. Akpek G, Chinratanalab W, Lee LA, et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant. 2003;9:46-51.
43. McKay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:63-66.
44. Lichtman SM, Attivissimo L, Goldman IS, et al. Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol. 1999;61:242-264.
45. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993;11:768-770.
46. Raderer M, Scheithauer W. Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. Scand J Rheumatol. 1994;23:291-292.
47. Warner E, Keshavjee al-N, Shupak R, et al. Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol. 1997; 20:322-326.
48. Creamer P, Lim K, George E, et al. Acute inflammatory polyarthritis in association of tamoxifen. Br J Rheumatol. 1994;33:583-585.
49. Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination therapy for testicular cancer. Ann Intern Med. 1981;95:288-295.
50. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of three cases. J Rheumatol. 1992;19:294-296.
51. Behrens S, Reuther T, von Kobyletzki G, et al. Bleomycin-induced PSS-like pseudoscleroderma: case report and review of the literature. Hautarzt. 1998;49:725-729.
52. Wandl UB, Nagel-Hiemke M, May D, et al. Lupus like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol. 1992;65:70-74.
53. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid. Ann Intern Med. 1991;115:178-183.
54. Schulte CM, Beelen DW. Avascular osteonecrosis after allogeneic hematopoietic stem-cell transplantation: diagnosis and gender matter. Transplantation. 2004;78:1055-1063.
55. Mendenhall WM. Mandibular osteoradionecrosis. J Clin Oncol. 2004; 22:4867-4868.
56. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007; 65:1328-1331.
57. Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist. 2006;11:718-731.
58. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245:452-461.
59. Zakaria S, Johnson R, Pockaj BA, et al. Breast cancer presenting as unilateral arm edema. J Gen Intern Med. 2007;22:675-676.
60. Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer. Ann Surg Oncol. 2007; 14:1904-1908.
61. Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv. 2007;1:261-274.
62. Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2007;68:1131-1139.
63. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among longterm survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435-2443.
64. OelkersW. Adrenal insufficiency. N Engl J Med. 1996;335:1206-1212.
65. Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992;10:574-579.
66. Tarrass F, Benmensour M, Bayla A. End stage renal disease following carboplatin chemotherapy for a nasopharyngeal carcinoma. Ren Fail. 2007;29:1049-1051.
67. Langer T, Stohr LT, Biclack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer. 2004;42:373-379.
68. Lhotta K, Kuhr T, Rumpelt H, et al. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol. 1999;19:590-593.
69. Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007;39:223-229.
70. Custodio CM. Neuromuscular complications of cancer and cancer treatments. Phys Med Rehabil Clin N Am. 2008;19:27-45.
71. Schlegel U, Pels H, Oehring R, et al. Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol. 1999;43:277-286.
72. Johnson BE, Patronas N, Hayes W, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol. 1990;8:48-56.
73. Gospodarowicz M. Testicular cancer patients: considerations in longterm follow-up. Hematol Oncol Clin N Am. 2008;22:245-255.
74. Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51:19-40.
75. Bernstein PS, DellaCroce JL. Diagnostic and therapeutic challenges: tamoxifen toxicity. Retina. 2007;27:982-988.
76. Barabino S, Raghavan A, Loeffler J, et al. Radiotherapy-induced ocular surface disease. Cornea. 2005;24:909-914.
77. Brown GC, Shields JA, Sanborn G, et al. Radiation retinopathy. Ophthalmology. 1982;89:1494-1501.
78. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004;15:503-507.
79. Bray LC, Carey PJ, Proctor SJ, et al. Ocular complications of bone marrow transplantation. Br J Ophthalmol. 1991;75:611-614.
80. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4-13.
81. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol. 1989;107:1343-1348.
82. Walsh T, Clark A, Parhad L, et al. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982;39:719-720.
83. Honore HB, Bentzen SM, Mailer K, et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol. 2002;65:9-16.
84. Gabriele P, Orecchia R, Magnano M, et al. Vestibular apparatus disorders after external radiation therapy for head and neck cancers. Radiother Oncol. 1992;25:25-30.